CPL 410 005
Alternative Names: CPL-410-005Latest Information Update: 28 Dec 2022
At a glance
- Originator Celon Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Solid-tumours in Poland
- 28 Oct 2021 No recent reports of development identified for preclinical development in Haematological-malignancies in Poland
- 13 Nov 2018 Preclinical trials in Solid tumours in Poland (unspecified route)